Since the introduction of immune checkpoint inhibitors (ICI) blocking the inhibitory T cell checkpoints PD-1 and CTLA-4, either sequentially or combined, five-year overall survival (OS) rates of up to 50% have been observed in patients with advanced stage melanoma [1]. Here, PDCD1 is linked to melanoma.